Overview

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2021-10-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal
Atezolizumab